Themes
Business
Talent
At the park
Communities
Jobs & internships
Events
News
Contact
A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By combining patient data, lab-based human cell models, and artificial intelligence, the MECHanistic PATHology (MechPath) approach allows researchers to identify patterns and make reliable predictions without relying on animal testing.
Key results so far:
Human cells used in lab models appear to retain a “disease memory,” continuing to respond as if they were still in the body, offering more realistic models for conditions like fibrosis.
The newly developed CELLS-PATH validation tools help lab-grown models gain approval faster, paving the way for wider adoption in drug research.
Thank you to everyone who joined us last Thursday at Grand Café de Stal. The room was full of energy, curiosity, and conversation as we explored the next wave of biotech...
At BIO International Convention in Boston, biotech ambition turns into partnership and progress. This year, Leiden Bio Science Park joined the Dutch delegation at the Netherlands...
We recently hosted Tjerk Opmeer from the Ministry of Economic Affairs at Leiden Bio Science Park to share insights into building a shared investment agenda for Dutch biotech....